Contemporary review of primary membranous nephropathy - Takeaways - MDSpire

Contemporary review of primary membranous nephropathy

  • By

  • Edward J. Filippone

  • John L. Farber

  • June 19, 2026

  • 0 min

Share

  • 1

    Primary membranous nephropathy (PMN) is an autoimmune disease characterized by autoantibodies targeting podocyte-associated antigens, primarily PLA2R.

  • 2

    PMN presents as nephrotic syndrome, with one-third of patients experiencing spontaneous remission and another third progressing to end-stage kidney disease (ESKD).

  • 3

    Treatment for PMN includes supportive anti-proteinuric therapy and immunosuppression based on KDIGO risk stratification, with rituximab for moderate to high-risk cases.

  • 4

    PLA2R antibody levels can be monitored to assess treatment response, with reemergence indicating potential relapse.

  • 5

    Transplantation is the optimal therapy for ESKD, but recurrence of PMN is common, necessitating protocol biopsy for PLA2R-positive cases.

Original Source(s)

Contemporary review of primary membranous nephropathy

  • by Edward J. Filippone, John L. Farber

  • June 19, 2026

Related Content

Most Miss Streamlined Neck Mass Dx Path

Same-visit biopsy and fewer empiric workup steps were linked to faster pathologic diagnosis in a retrospective analysis.

UK Diagnostic Backlog on the Rise

New report calls for National Health Service reforms as diagnostic waiting lists approach 2 million patients

  • June 19, 2026

  • 3 min
The Proteomics of Precision – with Jennifer Van Eyk

Ahead of ISC2026 in Prague, Jennifer Van Eyk explains how scalable LC-MS workflows and single-cell proteomics are helping reveal the biological differences that could make precision medicine a clinical reality